Printer Friendly

FDA APPROVES COHERENT LASERS FOR LUNG CANCER TREATMENT.

Coherent, Inc. (Nasdaq:COHR), Santa Clara, has announced the U.S. Food and Drug Administration's clearance of Photofrin(R) (porfimer sodium) for the palliative treatment of non-small cell late stage lung carcinoma. Photofrin is a photodynamic drug that utilizes Coherent's Lambda Plus(R) dye laser for activation. Photodynamic therapy (PDT) utilizes the combination of a light-activated drug and a specific wavelength of laser light to activate the drug. When the drug is activated by the laser light, a reaction is triggered that kills the host tumor cells. Bernard Couillaud, Coherent's president and CEO said, "Photodynamic therapy presents us with an opportunity to treat large numbers of people with cancer and in the future with potential treatments in ophthalmology and autoimmune disease." An estimated 171,500 Americans were diagnosed with lung cancer this year, the majority of which were in later stages of the disease. Approximately 20,000 to 25,000 of these patients will be candidates for this treatment. Earlier this year the FDA cleared Photofrin with the Lambda Plus for the treatment of early stage non-small cell lung carcinoma. The first clearance for this drug and laser combination was for the treatment of late stage esophageal cancer in 1995. Photofrin is produced by QLT PhotoTherapeutics Inc. (NASDAQ:QLTIF and TSE:QLT) a world leader in the development and commercialization of proprietary pharmaceutical products for use in photodynamic therapy. Founded in 1966, Coherent, Inc. is a Standard & Poor's SmallCap 600 company and a world leader in the design and manufacture of lasers and systems for medical, scientific and commercial applications. For more information, call (408)764-4168.
COPYRIGHT 1999 Worldwide Videotex
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1999 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Comment:FDA APPROVES COHERENT LASERS FOR LUNG CANCER TREATMENT.
Publication:Biotech Equipment Update
Geographic Code:1USA
Date:Feb 1, 1999
Words:266
Previous Article:PROTOCOL DROPS DEFRIBRILLATOR TECHNOLOGY.
Next Article:HP VUELINK BRINGS PUMP DATA TO PATIENT MONITORS.
Topics:


Related Articles
OFAC clears cancer drug for U.S. trials.
SLOAN CANCER VACCINE PHASE III STUDY BEGINS.
Life-saving cancer drugs not approved by the FDA.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters